41 results on '"Finke, J."'
Search Results
2. A score from the pre-transplant variables karyotype, monocytosis, circulating blasts and transfusion dependence predicts post-transplant survival after allogeneic stem cell transplantation for myelofibrosis: V775
3. Alternating courses of 3x CHOP and 3x DHAP plus Rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus Rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: Results of the MCL Younger Trial of the European mantle cell lymphoma network (MCL net): V116
4. Cytokeratin-18 is a useful serum biomarker for the early detection of acute intestinal graft-versus-host disease: V700
5. Alemtuzumab dose reduction in allogeneic PBSCT promotes early NK cell recovery: V125
6. Genetic material transference through apoptotic bodies: a novel mechanism of epithelial chimerism after allogeneic hematopoietic cell transplantation: V841
7. Immuno-Chemotherapy with Rituximab, Methotrexate, Lomustine, and Procarbazine in Patients older than 65 years with Primary CNS Lymphoma: V565
8. Shift to an alternative donor does not improve the outcome after second allogeneic stem cell transplantation (alloSCT) in acute leukaemia relapsing after a first alloSCT - a risk factor analysis by the German Stem Cell Registry (DRST): V545
9. Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial: V547
10. FAMILIAL MDS-RELATED AML - CAN THESE FAMILIES SERVE AS A MULTISTEP MODEL FOR LEUKAEMIC TRANSFORMATION IN MDS AND AML?: V376
11. ZNS - Lymphome: V118
12. Randomized Comparison of Autologous Peripheral Blood Stem Cell Transplantation and High Dose AraC as Late Consolidation in Adults with Standard Risk Acute Myeloid Leukemia Aged ≤ 60 Years: Results of a Prospective Multicenter Trial: O388
13. Allogeneic Peripheral Blood Stem Cell Tra Nsplantation (PBSCT) from an Unrelated Donor is a Reasonable Treatment Option for Older pts (>60 years) with High Risk AML or MDS: O390
14. Role of Consolidation Therapy in Adults with High Risk Acute Myeloid Leukemia Aged ≤ 60 Years: Results of a Prospective Multicenter Trial: O387
15. Reduced-Intensity Conditioning Lowers Treatment-Related Mortality of Allogeneic Stem Cell Transplantation for CLL: A Population-Matched Analysis: O294
16. A retrospective single-center study on 172 consecutive patients with multiple myeloma treated over a 10-year period: P713
17. Allogeneic hematopoetic stem cell transplantation from unrelated and related donors in 22 patients with progressive indolent lymphoma or myeloma: P526
18. Two-step immunoablative treatment with autologous peripheral blood stem cell transplantation for Crohnʼs disease and Colitis ulcerosa: P518
19. Reduced relapse incidence in poor risk patients using peripheral blood stem cells compared to bone marrow after allogeneic unrelated donor transplantation: P506
20. Induction of tumor reactive, allogeneic donor lymphocytes: P491
21. Prognosis of high risk soft tissue sarcoma patients after autologous peripheral blood stem cell transplantation: A retrospective analysis: V384
22. Primary CNS lymphoma - high dose chemotherapy with autologous PBSCT and hyperfractionated radiotherapy as firstline therapy - a multicenter phase II-study: V355
23. Treatment for Primary CNS Lymphoma (PCNSL): 3.2.11
24. High Grade Non-Hodgkinʼs Lymphoma: Risk Adapted Therapies: 3.2.7
25. Indications for High-Dose Chemotherapy (HDCT) and Autologous Hematopoietic Stem Cell Transplantation (ASCT): 2.5.7
26. Allogeneic Stem Cell Transplantation in Adult Patients with Leukemia and Lymphoma: 2.5.10
27. Allogeneic Hematopoietic Cell Transplantation: How Much Conditioning and How Much Graft versus Tumor Effect?: 2.5.2
28. Adoptive T Cell Transfer: 2.3.2
29. Prospective analysis of autologous hematopoietic stem cell transplantation (ASCT) in primary high-risk and relapsed lymphoma (L): Encouraging results and continuous challenge for the future: 818
30. Improved outcome in poor risk patients after allogeneic unrelated donor transplantation using PBSC compared to BM: 814
31. High Incidence of B-cell diseases in potential familiar donors of patients with multiple myeloma: 764
32. Favourable survival of cytogenetic IFN-responders after allogeneic stem cell transplantation (SCT) in chronic myeloid leukaemia (CML): 625
33. Improved survival after allogeneic stem- cell transplantation in CML patients in 1. chronic phase with unrelated donors compared to patients beyond 1. chronic phase: 614
34. Perforin/Granzyme is the predominant effector mechanism of CTL in Graft versus Leukemia reaction: 345
35. Allogeneic transplantation in the elderly (> 60 years): outcome after unrelated and related donor transplantation in patients with poor risk hematological malignancies: 314
36. Secondary allogeneic transplantation with an uniform fludarabine/thiotepa containing regimen improves survival in patients with relapse after autologous or allogeneic transplantation: 315
37. Detection of epithelial microchimerism in paraffin-embedded colon biopsies after hematopoietic stem cell transplantation (HSCT): 307
38. Immuntherapie durch allogene Stammzelltransplantation: 3.2.3 | 5
39. Therapiestrategien bei hochmalignen Lymphomen: 1.2.1 |4
40. Fatal Leukoencephalopathy after Reduced-Intensity Allogeneic Stem Cell Transplantation.
41. Meeting Report: Primary Central Nervous System Lymphoma: Standards Of Care And Future Perspectives.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.